Glyzenta Duo Tablet 2.5/500 mg
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
MFDS item code 201902224 · Approved 2019.04.11
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is effective in assisting blood sugar control in patients with type 2 diabetes when used in conjunction with dietary and exercise therapies. Linagliptin and metformin work together to help manage blood sugar more effectively. This contributes to maintaining stable blood sugar levels for diabetes management. Therefore, this medication is used for the improvement of blood sugar control in patients with type 2 diabetes.
The dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: An initial dose of this medication consisting of linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s previous metformin dose should be considered. When this medication is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administer with Caution to the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do Not Administer to the Following Patients).
This medication can cause serious metabolic complications such as lactic acidosis, so patients with poor kidney function or those with heart or liver disease should take special precautions. Patients allergic to any ingredients in this medication, or those with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, or severe renal impairment should not take this medication. Patients in acute conditions such as acute infections, dehydration, severe trauma, shock, or acute myocardial infarction should also avoid using this medication. Pregnant or breastfeeding women are advised not to take this medication, and those planning to become pregnant should consult a doctor. This medication has a risk of hypoglycemia, so blood sugar changes should be closely monitored when used alongside insulin or sulfonylureas. Elderly patients with impaired kidney function should have regular kidney function tests before taking this medication, and dosage adjustments may be necessary. Rare side effects such as acute pancreatitis or bullous pemphigoid can occur while taking this medication, so any abdominal pain or skin abnormalities should be reported to a physician immediately. The metformin component can cause vitamin B12 deficiency, so blood tests to check vitamin B12 levels are recommended during long-term use. This medication may interact with other drugs, so it is essential to inform the physician or pharmacist about any other medications being taken. Before and after radiological examinations using iodinated contrast agents, this medication should be temporarily discontinued, and resumed after kidney function is stabilized. Patients undergoing surgery should stop this medication 48 hours prior to the procedure and resume it only after kidney function has returned to normal following surgery. This medication is not recommended for children under 10 years of age, and safety and efficacy have not been sufficiently confirmed for adolescents aged 10 to 17 years. The effects on driving or operating machinery are unclear, so caution is advised after taking this medication. In case of an overdose, the risk of lactic acidosis is increased, so if symptoms occur, one should seek immediate medical treatment.
Lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity, angioedema, urticaria, reduced and deficient vitamin B12, taste disorders, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, severe and disability-associated arthralgia, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, small and large bowel inflammation, intestinal obstruction, gastritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorders, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, renal transplant failure, hypertension, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fractures, hand fractures, benign prostatic hyperplasia, pruritus, confusion state, nocturia, dermatitis, stomatitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, hypercholesterolemia, dizziness, drowsiness, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, voice disorder, epistaxis, hearing loss, erectile dysfunction, goiter, thyroid nodule, anxiety, insomnia, depression
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and humidity, so it should be stored in a tightly closed container. It is best to keep it at room temperature, between 1 degree and 30 degrees Celsius. This will help maintain the medication's effectiveness and prevent degradation.
Bright yellow, bi-convex, oval, film-coated tablet
10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box (10 tablets/PTP×3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.